To register: https://bit.ly/305jpF8 The 3rd and final webinar in the current LAB150-TIAP series will be held on Tuesday, March 23. Please see the link above to register. There are limited number of openings, so please register soon. Feel free to circulate to senior scientists in your…
News
Webinar February 24, 2021 – Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule
On February 24, LAB150 together with TIAP hosts a webinar entitled Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule. Please see the link below for more information and to register. There are limited number of openings, so please register soon. Feel free to circulate to senior…
TIAP & Amgen co-fund transformative projects to support new venture development
December 8, 2020 TIAP announces co-funding of transformative projects with Amgen to support new venture development Toronto Innovation Acceleration Partners (TIAP)Â is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto,…
Webinar: Staying on Target: Is your research program ready for drug discovery?
Staying on Target: How to Determine if Your Research Program is Ready for Drug Discovery LAB150 Presents: A 3-part Webinar Series on Drug Discovery and Development Register here: bit.ly/Stay-On-Target In the first of three webinars in the LAB150 series on drug discovery and development, we…
Project 7: Novel Therapeutic Agent for Immuno-Oncology from Sunnybrook Research Institute
Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his…
Funding for Sinai Health Netherton Syndrome project from partners Evotec and AmorChem
TORONTO, May 12, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in…
Project 6: KRAS Oncology Research
Toronto, ON, Dec. 12, 2019 (GLOBE NEWSWIRE) — The low survival rates of three of the four most lethal cancers in North America – pancreatic, colorectal and lung – are associated with KRAS mutations, a well-established cancer driver. Although there is an urgent need for…
Article: Accelerating Toronto’s Academic Innovation through LAB150
In this June 2019 article, Stephanie Oestreich, Executive Vice President, North American BRIDGEs Partnerships at Evotec SE, examines the reasoning behind creating LAB50, and the aspirations for the collaboration between Evotec and MaRS Innovation: Accelerating Toronto’s Academic Innovation through LAB150, June 2019
Drug Discovery Summit – June 2019
LAB150 hosted its very first Drug Discovery Summit on June 11, 2019 in the beautiful offices of JLABS Toronto. On hand were our team partners from Evotec as well as entrepreneurs and scientists who have collaborated with LAB150. With five projects funded, and with one…
Mental Health is the Focus of Our Fifth Project
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) — It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many antidepressant drugs on the market, most of these drugs need weeks to take…